Clinical Trials

120 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04585477 2026-02-10

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04966676 2026-01-08

ATLAS

5 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04765709 2025-12-16

BRIDGE

10 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06623656 2025-10-23

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

112 enrolled

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07084610 2025-08-22

Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

30 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06908733 2025-04-03

Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC

30 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06614231 2024-09-26

Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06313541 2024-06-05

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

146 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06424899 2024-05-22

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

92 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Phase 2 Unknown

132 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT04379739 2023-12-06

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

89 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05675033 2023-01-09

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Phase 2 Unknown

50 enrolled

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT05383001 2022-09-27

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03322566 2022-01-24

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Phase 2 Completed

233 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05055583 2021-09-24

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

Phase 2 Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00404703 2016-08-24

A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer

37 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00391586 2015-08-17

Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung

45 enrolled 4 charts